Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
November 03 2022 - 9:07AM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic
T-cell immunotherapy company, today announced that final data from
the Phase 2 study of posoleucel for the prevention of clinically
significant infections or diseases by multiple viruses following
allogeneic hematopoietic cell transplantation (allo-HCT) has been
accepted as an oral presentation at the 64th American Society of
Hematology (ASH) Annual Meeting to be held in New Orleans,
Louisiana, December 10-13, 2022. The presentation will include
final efficacy and safety results as well as posoleucel expansion
and persistence data.
Posoleucel is AlloVir’s lead investigational virus-specific T
cell (VST) therapy being developed as an off-the-shelf therapeutic
for the treatment or prevention of up to six devastating viruses
(adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human
herpesvirus-6 and JC virus) that have few to no effective treatment
or prevention options and can be life-threatening for allo-HCT
patients. These common viral infections present significant
challenges in the management of allo-HCT patients, with the
potential for prolonged hospitalization, increased risk for graft
versus host disease (GVHD), end-organ damage and death. Preventing
these viral infections and diseases – whether through the
prophylaxis of patients at high risk for viral reactivation or
through the preemptive treatment of patients with viral
reactivation who have not yet developed clinically significant
infections or disease – has the potential to fundamentally
transform the treatment landscape for allo-HCT.
“We are excited to share the final data from our Phase 2 study
of posoleucel for multi-virus prevention, which continue to support
the transformational potential of posoleucel. Based on preliminary
data from this study, AlloVir initiated a global Phase 3
multi-virus prevention study earlier this year. We are pleased with
the enthusiasm we are seeing from leading transplant centers around
the world participating in the trial,” said Diana Brainard, M.D.,
CEO, AlloVir.
Details of the presentation at ASH are as follows:
Final Clinical Outcomes from a Phase 2 Trial of Posoleucel,
an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the
Prevention of Clinically Significant Viral Infections Post-HCT
(Abstract 362) Session 704: Cellular Immunotherapies: Early
Phase and Investigational Therapies: CAR T in Multiple Myeloma and
T-cell Therapies After Allo-HCT Presentation Time: Saturday,
December 10, 2022, 4:15 p.m. CT (5:15 p.m. ET)
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company
with a focus on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company’s innovative and proprietary technology
platforms leverage off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir’s technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio. For more information, visit
www.allovir.com or follow us on Twitter or LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding AlloVir’s development and regulatory status of our
product candidates, the planned conduct of its preclinical studies,
and clinical trials and its prospects for success in those studies
and trials, and its strategy, business plans and focus. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties, and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those related to AlloVir’s financial results, the
timing for the initiation and successful completion of AlloVir’s
clinical trials of its product candidates, whether and when, if at
all, AlloVir’s product candidates will receive approval from the
U.S. Food and Drug Administration, or FDA, or other foreign
regulatory authorities, competition from other biopharmaceutical
companies, the impact of the COVID-19 pandemic on AlloVir’s product
development plans, supply chain, and business operations and other
risks identified in AlloVir’s SEC filings, including but not
limited to the risks discussed in AlloVir's Annual Report on Form
10-K for the year ended December 31, 2021, and in our other filings
with the SEC. AlloVir cautions you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made. AlloVir disclaims any obligation to publicly update
or revise any such statements to reflect any change in expectations
or in events, conditions, or circumstances on which any such
statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent AlloVir’s views only as
of the date hereof and should not be relied upon as representing
its views as of any subsequent date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221102006217/en/
Media and Investor Contact: Sonia Choi AlloVir
schoi@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jun 2024 to Jul 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jul 2023 to Jul 2024